Venrock Healthcare Capital Partners III, L.P. and affiliated entities filed a Form 4 with the SEC on October 30, 2026, disclosing five open-market purchases of Lycia Therapeutics, Inc. common stock executed between October 28 and October 30, 2026.

Key Highlights

  • Five purchase transactions: The Venrock Healthcare group acquired shares of Lycia Therapeutics common stock across three consecutive trading days, October 28, 29, and 30, 2026.
  • October 28 first tranche: 10,570 shares were acquired at a weighted average price of $25.23 per share, with individual transaction prices ranging from $24.77 to $25.50.
  • October 28 second tranche: 4,430 shares were acquired at a weighted average price of $25.97 per share, with prices ranging from $25.88 to $26.00.
  • October 29 purchase: 1,000 shares were acquired at a weighted average price of $26.33 per share, with prices ranging from $26.26 to $26.40.
  • October 30 purchases: 8,804 shares at a weighted average of $26.27 and 200 shares at a weighted average of $26.86 were acquired, bringing cumulative beneficial ownership to 6,850,237 shares, according to the filing.
  • Multiple reporting persons: The filing was made jointly by nine reporting persons, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, and affiliated management entities, as well as individuals Bong Y. Koh and Nimish P. Shah.
  • Ownership classification: All reported shares are held indirectly, described in the filing as "By Funds."

Venrock Healthcare Group Adds to Lycia Therapeutics Position Across October 28-30, 2026

According to the filing, Venrock Healthcare Capital Partners III, L.P. and a group of affiliated entities and individuals reported five separate purchases of common stock in Lycia Therapeutics, Inc. (NASDAQ:LYCA) over three trading days. The transactions were all coded "P," indicating open-market purchases, and all shares were acquired rather than disposed of. Each reported price is described in the filing as a weighted average, with the actual individual transaction prices spanning ranges disclosed in footnotes.

The filing identifies the shares as held indirectly by the reporting persons through multiple funds. The first October 28 tranche of 10,570 shares was allocated across Venrock Healthcare Capital Partners III, L.P. (VHCP3), VHCP Co-Investment Holdings III, LLC (VHCP Co-3), and Venrock Healthcare Capital Partners EG, L.P. (VHCP EG), consisting of 4,804, 481, and 5,285 shares, respectively, according to footnote 1. Subsequent transactions followed a similar allocation structure among the same funds, as detailed in footnotes 7 and 10 of the filing.

The filing further discloses that VHCP Management III, LLC is the general partner of VHCP3 and the manager of VHCP Co-3, while Bong Koh and Nimish Shah are the voting members of the relevant management entities. Each of these management entities and individuals expressly disclaims beneficial ownership over the shares "except to the extent of its or his indirect pecuniary interest therein," according to the filing's footnotes. Following all five reported transactions, the aggregate beneficial ownership reported by the group stood at 6,850,237 shares, held across VHCP3, VHCP Co-3, VHCP EG, and Venrock Healthcare Capital Partners XP, L.P.

What Was Disclosed

This Form 4 filing covers five purchases of Lycia Therapeutics common stock by the Venrock Healthcare group between October 28 and October 30, 2026, with all shares acquired indirectly through affiliated funds and reported at weighted average prices. Aggregate beneficial ownership after the final transaction was reported as 6,850,237 shares.